tiprankstipranks
Advertisement
Advertisement
Abbisko Showcases Broad Oncology Pipeline with Pan‑KRAS Data at 2026 AACR
PremiumCompany AnnouncementsAbbisko Showcases Broad Oncology Pipeline with Pan‑KRAS Data at 2026 AACR
2M ago
Abbisko Cayman to Raise HK$517 Million via Discounted Share Placing for R&D Push
Premium
Company Announcements
Abbisko Cayman to Raise HK$517 Million via Discounted Share Placing for R&D Push
2M ago
Abbisko Grants 290,000 Share Options to Employees Under Post-IPO Scheme
Premium
Company Announcements
Abbisko Grants 290,000 Share Options to Employees Under Post-IPO Scheme
2M ago
Abbisko Wins FDA Rare Pediatric Disease Status for Achondroplasia Drug ABSK061
PremiumCompany AnnouncementsAbbisko Wins FDA Rare Pediatric Disease Status for Achondroplasia Drug ABSK061
3M ago
Abbisko’s TGCT Drug Pimicotinib Clears Key Global Milestone With Lancet Phase 3 Publication
Premium
Company Announcements
Abbisko’s TGCT Drug Pimicotinib Clears Key Global Milestone With Lancet Phase 3 Publication
3M ago
Abbisko Advances KRAS G12D Cancer Program With First Patient Dosed in ABSK141 Trial
Premium
Company Announcements
Abbisko Advances KRAS G12D Cancer Program With First Patient Dosed in ABSK141 Trial
3M ago
Abbisko Wins FDA Fast Track for Precision Liver Cancer Drug Irpagratinib
PremiumCompany AnnouncementsAbbisko Wins FDA Fast Track for Precision Liver Cancer Drug Irpagratinib
4M ago
Abbisko’s TGCT Drug Pimicotinib Wins FDA NDA Acceptance After Strong Phase III Data
Premium
Company Announcements
Abbisko’s TGCT Drug Pimicotinib Wins FDA NDA Acceptance After Strong Phase III Data
5M ago
Abbisko Wins NMPA IND Clearance for Novel KRAS G12D Cancer Drug ABSK141
Premium
Company Announcements
Abbisko Wins NMPA IND Clearance for Novel KRAS G12D Cancer Drug ABSK141
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100